bearish
Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)
393 Views16 Oct 2018 17:18
Innovent Biologics launched the institutional book building today and intends to raise USD 377 to USD 423 million, with an implied market...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Innovent Biologics (信达生物) Placement - Selling upon Lock-Up Expiry16 Apr 2019
- Keytruda Approved for Lung Cancer Treatment in China - A Review of PD-1 Battle Field11 Apr 2019
- Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?01 Nov 2018
- Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)16 Oct 2018
- Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)10 Oct 2018
- Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)13 Sep 2018
x